Metforminium Decavanadate as a Potential Metallopharmaceutical Drug for the Treatment of Diabetes Mellitus

Table 1

Metabolite control, renal and hepatic toxicological profile with dose of 5.0 μM MetfDeca.

Metabolite	Control	Alloxan + 0.0 μM (MetfDeca)	Alloxan + 5.0 μM (MetfDeca)
Insulin (μU/mL)		▼
Glucose (mg/dL)		▲
Triglycerides (mg/dL)		▼	▲
Cholesterol (mg/dL)
Total bilirubin (mg/dL)		▲
AST (U/L)		▲	▼
ALT (U/L)		▲	▲
γGT (U/L)		▲
ALP (U/L)		▲	▼
Sodium (mmol/L)		▼	▼
Potassium (mmol/L)		▼
Urea		▲	▲
Creatinine		▲	▲

The serum parameters are the average of 10 separate experimental animals ± SEM. ▲ indicates significant difference with values above the control group, while ▼ indicates significant difference with values below the control group with by Student’s -test. AST: aspartate transaminase, ALT: alanine aminotransferase, γGT: Gamma-glutamyl transpeptidase, and ALP: alkaline phosphatase.